MRSA Testing Devices Sales

MRSA Testing Devices Sales Market Outlook

The global MRSA testing devices market is poised for significant growth, projected to reach approximately USD 3.1 billion by 2035, growing at a CAGR of around 8.5% during the forecast period from 2025 to 2035. This growth is attributed to the rising prevalence of Methicillin-resistant Staphylococcus aureus (MRSA) infections, increased awareness regarding infection control practices, and the growing demand for rapid and accurate diagnostic tools in healthcare settings. Moreover, advancements in technology, including the development of point-of-care testing devices and molecular diagnostics, are expected to significantly enhance the speed and accuracy of MRSA detection. These factors collectively contribute to the market's optimistic outlook, as healthcare systems increasingly prioritize effective management of hospital-acquired infections.

Growth Factor of the Market

The MRSA testing devices market is witnessing robust growth, primarily driven by the escalating incidence of MRSA infections across various regions. As healthcare facilities strive to mitigate the risks of hospital-acquired infections, the need for effective and timely diagnostic solutions has never been more critical. Furthermore, the expansion of healthcare infrastructure in developing nations, coupled with a growing emphasis on preventive healthcare, is pushing the adoption of advanced MRSA testing technologies. Additionally, the rise in research and development activities aimed at improving testing methodologies is expected to propel market growth. The increasing awareness among patients and healthcare providers about the significance of early diagnosis and treatment of MRSA infections further fuels demand for these testing devices, making it a key growth driver in the market.

Key Highlights of the Market

• The global MRSA testing devices market is expected to witness substantial growth driven by increasing MRSA infection rates.
• Technological advancements, particularly in molecular diagnostics, are enhancing testing accuracy and speed.
• Hospitals and diagnostic laboratories are the primary end-users of MRSA testing devices, contributing significantly to market revenue.
• North America is the leading region in terms of market share due to high healthcare expenditure and advanced healthcare infrastructure.
• Growing awareness about infection control practices is fostering the adoption of MRSA testing solutions globally.

By Product Type

PCR Assays:

Polymerase Chain Reaction (PCR) assays have emerged as a leading product type in the MRSA testing devices market due to their high sensitivity and specificity in detecting MRSA strains. PCR technology allows for the rapid amplification of bacterial DNA, enabling timely diagnosis of infections. The increasing demand for fast and accurate testing results in clinical settings is propelling the adoption of PCR assays. Furthermore, advancements in PCR technology, including real-time PCR, are enhancing the user experience with quicker turnaround times and reduced manual intervention. As healthcare providers focus on improving patient outcomes, the reliance on PCR assays for MRSA detection is expected to remain a significant trend in the market.

Immunoassays:

Immunoassays are another vital segment in the MRSA testing devices market, offering a reliable alternative for the detection of MRSA infections. These assays utilize antibodies to detect specific antigens associated with MRSA bacteria, providing a qualitative or quantitative assessment of the infection. The simplicity and cost-effectiveness of immunoassays make them favorable for use in various healthcare settings, including clinics and hospitals. Additionally, advancements in rapid immunoassay technologies have led to the availability of point-of-care testing options, allowing for immediate results and facilitating prompt clinical decision-making. As the healthcare community increasingly values rapid diagnostics, the demand for immunoassays is projected to grow steadily.

Molecular Diagnostics:

Molecular diagnostics represent a rapidly growing segment of the MRSA testing devices market, leveraging cutting-edge technologies to detect genetic material from MRSA pathogens. This methodology offers unparalleled accuracy and sensitivity compared to traditional culture methods. The growth of molecular diagnostics is driven by the increasing need for rapid pathogen identification, particularly in critical care settings where timely intervention is essential. The integration of molecular diagnostics into routine screening programs in hospitals enhances infection control practices and reduces the transmission rates of MRSA. As the focus on personalized medicine intensifies, the molecular diagnostics segment is expected to witness substantial expansion in the coming years.

Culture-Based Tests:

Culture-based tests have been the traditional gold standard for MRSA detection, providing a reliable means of identifying bacterial strains through isolation and growth. While newer technologies are gaining popularity, culture-based tests remain an essential component of comprehensive diagnostic approaches. These tests allow for the determination of antibiotic susceptibility, which is crucial for effective treatment planning. However, the relatively longer turnaround time associated with culture methods compared to molecular tests poses a challenge. Despite this limitation, culture-based tests are still widely utilized, particularly in research settings and clinical laboratories, where accurate characterization of MRSA strains is necessary for epidemiological studies and surveillance.

Others:

This category encompasses various emerging testing methodologies that do not fall into the aforementioned segments, such as next-generation sequencing and biosensors. These innovative technologies offer the potential for advanced diagnostic capabilities, including multiplex detection of multiple pathogens simultaneously. The growing research and development efforts in this area are expected to lead to the introduction of novel MRSA testing devices, further enhancing the market landscape. As healthcare providers seek to integrate comprehensive testing solutions into their workflows, the adoption of these alternative methodologies is anticipated to increase, contributing to the overall growth of the MRSA testing devices market.

By Application

Hospitals:

Hospitals represent one of the largest applications for MRSA testing devices, as they are high-risk environments for the transmission of MRSA infections. With the increasing focus on infection prevention and control measures, hospitals are investing in advanced diagnostic technologies to quickly identify and manage MRSA cases. The implementation of routine screening protocols for high-risk patients and healthcare workers is driving the demand for MRSA testing devices within hospital settings. Moreover, the need for rapid decision-making in critical care situations necessitates the use of efficient testing solutions, further propelling the adoption of these devices in hospitals. As hospitals continue to prioritize patient safety and quality care, the application of MRSA testing devices is expected to grow significantly.

Clinics:

Clinics play a crucial role in the detection and management of MRSA infections, particularly in outpatient settings where early diagnosis can prevent further spread. The increasing prevalence of MRSA infections in community settings has heightened the need for clinics to adopt reliable testing methods. MRSA testing devices that provide rapid results are particularly beneficial in clinic environments, allowing healthcare providers to make timely treatment decisions. Additionally, the growing trend of point-of-care testing in clinics is supporting the expansion of MRSA testing technologies, facilitating immediate diagnosis and improving patient outcomes. As clinics strive to enhance their diagnostic capabilities, the demand for MRSA testing devices is expected to see considerable growth.

Diagnostic Laboratories:

Diagnostic laboratories serve as pivotal players in the MRSA testing landscape, offering comprehensive testing services for accurate pathogen identification. These laboratories often utilize a broad array of testing methods, including molecular diagnostics, culture-based tests, and immunoassays, to meet the diverse needs of healthcare facilities and physicians. The increasing complexity of MRSA infections and the need for precise antibiotic susceptibility testing further underscore the importance of diagnostic laboratories in the overall healthcare ecosystem. With the rise in demand for accurate and swift diagnostic services, diagnostic laboratories are expected to continue investing in advanced MRSA testing technologies, propelling market growth.

Others:

The "Others" segment encompasses various applications of MRSA testing devices in specialized settings, including research institutes and public health organizations. Research institutes utilize MRSA testing devices for epidemiological studies, surveillance, and the investigation of outbreak sources. Public health organizations also rely on these devices for monitoring community-acquired MRSA infections and implementing intervention strategies. The need for research and data collection to inform public health policies further drives the demand for MRSA testing technologies in these specialized applications. As awareness of MRSA continues to grow, the significance of this segment is expected to increase, contributing to the overall expansion of the market.

By End User

Hospitals:

Hospitals constitute a primary end-user segment for MRSA testing devices due to the critical need for infection control in healthcare settings. The high volume of patients and the constant risk of hospital-acquired infections make hospitals a focal point for implementing advanced diagnostic solutions. The integration of MRSA testing devices into hospital protocols not only facilitates timely interventions but also enhances infection prevention strategies. Hospitals are increasingly adopting point-of-care testing options to expedite diagnosis, ensuring that appropriate treatment measures are initiated without delay. As the healthcare landscape continues to evolve with a focus on patient safety, the hospital segment is anticipated to remain a significant contributor to the growth of the MRSA testing devices market.

Diagnostic Centers:

Diagnostic centers are crucial players in the MRSA testing devices market, providing specialized testing services to both healthcare providers and patients. These centers often offer a wide range of testing options, including molecular diagnostics and immunoassays, catering to the growing demand for rapid and accurate MRSA detection. The convenience and accessibility of diagnostic centers allow individuals to obtain testing without the need for hospital admission, making them an attractive option for outpatient care. Moreover, the increasing collaboration between diagnostic centers and hospitals for referral services is driving the integration of advanced MRSA testing solutions. As the emphasis on timely diagnosis and treatment continues to rise, the role of diagnostic centers in the MRSA testing landscape is expected to expand.

Research Institutes:

Research institutes are instrumental in the advancement of MRSA testing technologies, focusing on the development of innovative solutions and methodologies. These institutions conduct extensive studies to better understand MRSA epidemiology, resistance mechanisms, and effective diagnostic approaches. The collaboration between research institutes and healthcare providers is essential for translating research findings into clinical practice, ultimately enhancing patient care. The insights gained from research activities contribute to the development of novel MRSA testing devices that meet the evolving needs of healthcare systems. As research endeavors continue to yield valuable data, the involvement of research institutes in the MRSA testing devices market is expected to grow.

Others:

The "Others" segment includes various end users such as public health organizations and academic institutions that utilize MRSA testing devices for different purposes. Public health organizations rely on these devices for surveillance, monitoring, and outbreak investigations, aiming to inform policies and improve public health initiatives. Academic institutions leverage MRSA testing technologies for educational purposes and research projects, contributing to a deeper understanding of infection dynamics. As the importance of MRSA management becomes increasingly recognized, the demand for testing devices from these end users is likely to increase, supporting the overall market growth.

By Technology

Polymerase Chain Reaction:

Polymerase Chain Reaction (PCR) technology is at the forefront of MRSA testing due to its ability to amplify specific DNA sequences, allowing for the rapid detection of MRSA strains. PCR-based methods provide unmatched sensitivity and specificity, enabling healthcare providers to obtain accurate results in a fraction of the time compared to traditional culture methods. The increasing reliance on PCR technology is driven by the need for prompt diagnosis, particularly in emergency and critical care settings, where time-sensitive decisions are crucial. As advancements in PCR technology continue to emerge, including the development of multiplex assays that can detect multiple pathogens simultaneously, the segment's growth is expected to accelerate.

Enzyme-Linked Immunosorbent Assay:

The Enzyme-Linked Immunosorbent Assay (ELISA) is widely employed in the MRSA testing landscape due to its capacity for detecting specific antigens associated with MRSA bacteria. ELISA tests offer a balance of sensitivity and ease of use, making them suitable for various healthcare settings, from hospitals to outpatient clinics. The growing preference for rapid testing solutions has fueled the adoption of ELISA-based MRSA testing devices, particularly in point-of-care applications. The simplicity of the procedure, coupled with the ability to produce results quickly, enhances its appeal for healthcare providers seeking efficient diagnostic options. The ELISA segment is poised for growth as the focus on infection control intensifies.

Microarrays:

Microarray technology represents an innovative approach in the MRSA testing devices market, allowing for the simultaneous detection of multiple pathogens in a single test. This high-throughput methodology enables comprehensive screening for MRSA and other bacterial infections, significantly streamlining the diagnostic process. The increased efficiency offered by microarrays is particularly valuable in laboratory settings where large volumes of samples are processed. As the demand for multiplex testing solutions grows, the microarray segment is expected to expand, providing healthcare providers with advanced tools for accurate and rapid MRSA detection. The continuous advancement in microarray technology is likely to drive further innovation in this area.

Others:

The "Others" segment encompasses emerging technologies in MRSA testing, including next-generation sequencing and biosensors, which offer promising alternative approaches for pathogen detection. Next-generation sequencing provides comprehensive genomic information about MRSA strains, facilitating not only identification but also insights into resistance patterns. Biosensors, on the other hand, enable real-time detection of MRSA with high sensitivity, allowing for immediate clinical decision-making. These technologies represent the future of MRSA testing and are gaining traction in research and clinical applications. As the healthcare sector continues to embrace innovation, the "Others" segment is expected to contribute to the evolving landscape of MRSA testing devices.

By Region

The regional analysis of the MRSA testing devices market reveals significant variations in market size and growth potential across different areas. North America holds the largest market share, driven by advanced healthcare infrastructure, high levels of healthcare expenditure, and a strong emphasis on infection control measures. The region is expected to witness a CAGR of approximately 8% during the forecast period, as hospitals and diagnostic laboratories increasingly integrate cutting-edge MRSA testing technologies into their operations. The United States, in particular, stands out as a key contributor to this growth, given its strong healthcare system and increased awareness regarding the need for effective MRSA management.

In Europe, the MRSA testing devices market is also experiencing substantial growth, owing to the implementation of strict infection control policies and rising healthcare investments. The European market is characterized by a progressive approach to healthcare, with countries such as Germany, the United Kingdom, and France leading in technological adoption. The focus on early diagnosis and effective treatment strategies for MRSA infections is expected to drive the demand for testing devices in this region. Additionally, the growing collaboration between healthcare providers and research institutions to enhance MRSA testing methodologies contributes to the overall growth of the market in Europe. As a result, the European MRSA testing devices market is projected to grow at a healthy pace throughout the forecast period.

Opportunities

The MRSA testing devices market presents numerous opportunities for growth, particularly in emerging economies where healthcare infrastructure is rapidly developing. As these regions invest in improving healthcare services, the demand for advanced diagnostic technologies is expected to rise. Hospitals and clinics in developing countries are increasingly recognizing the importance of timely and accurate MRSA detection in preventing healthcare-associated infections. This shift creates a significant opportunity for manufacturers of MRSA testing devices to expand their presence in these untapped markets, offering innovative solutions tailored to local needs. Furthermore, partnerships with local healthcare providers and government agencies can facilitate market entry and enhance accessibility to advanced testing technologies, driving overall growth in these regions.

Another burgeoning opportunity lies in the integration of digital health solutions with MRSA testing devices. The increasing adoption of telemedicine and digital health platforms is reshaping the healthcare landscape, allowing for improved patient monitoring and management of infectious diseases. By developing testing devices that are compatible with digital health solutions, manufacturers can enhance the usability and accessibility of MRSA diagnostics. For instance, devices that can transmit results directly to electronic health records or mobile applications can streamline the diagnostic process, allowing healthcare providers to make faster clinical decisions. The convergence of MRSA testing with digital health technologies presents a promising avenue for innovation and growth in the market.

Threats

Despite the positive outlook for the MRSA testing devices market, several threats may hinder its growth trajectory. One of the primary challenges is the presence of stringent regulatory requirements for medical devices, which can delay product approvals and market entry. Compliance with regulations set by bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) necessitates comprehensive clinical trials and quality assurance processes, potentially stalling innovation and limiting the introduction of new testing solutions. Additionally, the high costs associated with research and development can deter smaller companies from entering the market, leading to reduced competition and innovation.

Another significant threat is the potential for market saturation as more players enter the MRSA testing devices landscape. As competition increases, it may result in price wars, ultimately affecting profit margins for manufacturers. Furthermore, the rapid pace of technological advancement means that companies must continuously invest in research and development to stay relevant. The emergence of alternative testing methods, such as at-home testing kits or decentralized testing solutions, can also pose a threat to traditional MRSA testing devices, necessitating a reevaluation of strategies to maintain market share. As the market evolves, manufacturers must navigate these challenges carefully to sustain growth and ensure the continued efficacy of their products.

Competitor Outlook

• Thermo Fisher Scientific Inc.
• Siemens Healthineers
• Roche Diagnostics
• BD (Becton, Dickinson and Company)
• bioMérieux SA
• Abbott Laboratories
• Cepheid, Inc.
• Hologic, Inc.
• Quidel Corporation
• Agilent Technologies, Inc.
• Genomica S.A.U.
• Danaher Corporation
• Bruker Corporation
• Mesa Biotech, Inc.
• Myriad Genetics, Inc.

The competitive landscape of the MRSA testing devices market is characterized by the presence of both established players and emerging companies, all vying for market share in an increasingly crowded space. Major companies like Thermo Fisher Scientific, Siemens Healthineers, and Roche Diagnostics are leveraging their extensive research and development capabilities to innovate and introduce new testing technologies. These companies often have strong distribution networks and established relationships with healthcare providers, enabling them to maintain a competitive edge. Furthermore, their ability to offer a comprehensive suite of diagnostic solutions positions them favorably in the market, providing healthcare professionals with integrated testing options for effective patient management.

In addition to large players, several smaller companies and startups are making significant strides in the MRSA testing devices market, focusing on niche areas and innovative technologies. For instance, companies like Cepheid and Hologic are gaining recognition for their rapid molecular diagnostic solutions, which offer quick turnaround times essential for improving patient outcomes. These emerging players are often agile and responsive to market needs, allowing them to capitalize on specific trends such as point-of-care testing and digital health integration. Collaborations with research institutions and healthcare organizations further bolster their potential for growth, as they work to develop cutting-edge solutions tailored to the evolving healthcare landscape.

As the market continues to evolve, partnerships and collaborations will play a crucial role in shaping the competitive landscape of MRSA testing devices. Companies are increasingly recognizing the value of strategic alliances with technology providers, research institutions, and healthcare systems to enhance their product offerings and expand their market reach. By leveraging each other's strengths, these partnerships can foster innovation, accelerate the development of new testing solutions, and improve overall patient care. Additionally, the focus on personalized medicine and tailored healthcare solutions will drive further collaboration among market players, ultimately shaping the future direction of the MRSA testing devices market.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Cepheid, Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Hologic, Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Genomica S.A.U.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Roche Diagnostics
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Bruker Corporation
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Mesa Biotech, Inc.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Quidel Corporation
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Abbott Laboratories
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Danaher Corporation
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Siemens Healthineers
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 bioMérieux SA
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Myriad Genetics, Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Agilent Technologies, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Thermo Fisher Scientific Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 BD (Becton, Dickinson and Company)
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 MRSA Testing Devices Sales Market, By End User
    • 6.1.1 Hospitals
    • 6.1.2 Diagnostic Centers
    • 6.1.3 Research Institutes
    • 6.1.4 Others
  • 6.2 MRSA Testing Devices Sales Market, By Technology
    • 6.2.1 Polymerase Chain Reaction
    • 6.2.2 Enzyme-Linked Immunosorbent Assay
    • 6.2.3 Microarrays
    • 6.2.4 Others
  • 6.3 MRSA Testing Devices Sales Market, By Application
    • 6.3.1 Hospitals
    • 6.3.2 Clinics
    • 6.3.3 Diagnostic Laboratories
    • 6.3.4 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 MRSA Testing Devices Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global MRSA Testing Devices Sales market is categorized based on

By Application

• Hospitals
• Clinics
• Diagnostic Laboratories
• Others

By End User

• Hospitals
• Diagnostic Centers
• Research Institutes
• Others

By Technology

• Polymerase Chain Reaction
• Enzyme-Linked Immunosorbent Assay
• Microarrays
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Thermo Fisher Scientific Inc.
• Siemens Healthineers
• Roche Diagnostics
• BD (Becton, Dickinson and Company)
• bioMérieux SA
• Abbott Laboratories
• Cepheid, Inc.
• Hologic, Inc.
• Quidel Corporation
• Agilent Technologies, Inc.
• Genomica S.A.U.
• Danaher Corporation
• Bruker Corporation
• Mesa Biotech, Inc.
• Myriad Genetics, Inc.